AXIM Biotechnologies, Inc. announced that it has received an initial order of 19,000 point-of-care diagnostic tests and 100 readers targeting ocular surface diseases through its exclusive global commercialization partner Verséa Ophthalmics, LLC, marking the Company's first large-scale revenue generating order. The order is part of the recently announced exclusive global commercialization agreement reached between Verséa and AXIM to support the commercial launch of sales at the 2022 American Academy of Ophthalmology conference in Chicago. The order represents the largest revenue-generating event in the history of the Company.

AXIM has successfully completed manufacturing and is preparing the order for shipment from its lab facilities in San Diego, California as per Verséa's direction. The order includes both the tear based tests for Lactoferrin and Immunoglobulin E as well as the associated digital reader that allows for quantitative test results. The tests provide doctors with access to real-time quantitative results within 10 minutes, allowing them to more accurately diagnose and prescribe targeted therapy to patients, leading to overall improved personalized patient care.

Both tests are FDA-cleared and have dedicated Medicare CPT codes that allow for rapid POC diagnosis of common ocular conditions such as dry eye disease and allergic conjunctivitis.